MRK: Achieves Phase 3 Win
Merck's investigational therapy tulisokibart achieves primary endpoint in Phase 3 study for ulcerative colitis
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.